Setmelanotide
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypothalamic Obesity
Conditions
Hypothalamic Obesity
Trial Timeline
Jun 7, 2021 → Jun 28, 2022
NCT ID
NCT04725240About Setmelanotide
Setmelanotide is a phase 2 stage product being developed by Rhythm Pharmaceuticals for Hypothalamic Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT04725240. Target conditions include Hypothalamic Obesity.
What happened to similar drugs?
1 of 3 similar drugs in Hypothalamic Obesity were approved
Approved (1) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06772597 | Phase 2 | Active |
| NCT06596135 | Phase 3 | Recruiting |
| NCT04966741 | Phase 3 | Completed |
| NCT04725240 | Phase 2 | Completed |
| NCT04348175 | Phase 1 | Completed |
| NCT03651765 | Phase 2/3 | Completed |
| NCT03262610 | Phase 2 | Completed |
| NCT03013543 | Phase 2 | Completed |
Competing Products
7 competing products in Hypothalamic Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Octreotide | Novartis | Approved | 43 |
| Mibavademab | Regeneron Pharmaceuticals | Phase 2 | 42 |
| Part A: RM-718 or placebo (matched to specific RM-718 dose cohort) + Part B: RM-718 or placebo (matched to specific RM-718 dose cohort) + Part C: RM-718 + Part D: RM-718 | Rhythm Pharmaceuticals | Phase 1/2 | 36 |
| Setmelanotide + Placebo | Rhythm Pharmaceuticals | Phase 3 | 41 |
| Setmelanotide + Placebo | Rhythm Pharmaceuticals | Phase 3 | 44 |
| Bivamelagon | Rhythm Pharmaceuticals | Phase 2 | 39 |
| LB54640 + Placebo | Rhythm Pharmaceuticals | Phase 2 | 32 |